查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
核酸治疗药的CDMO市场 - 全球及各地区分析:各化学合成方法，各产品，各技术，各终端用户，各地区 - 分析与预测(2023年～2033年)
市场调查报告书
商品编码
1262768

核酸治疗药的CDMO市场 - 全球及各地区分析:各化学合成方法，各产品，各技术，各终端用户，各地区 - 分析与预测(2023年～2033年)

Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis: Focus on Chemical Synthesis Method, Product, Technology, Disease Type, End User, and Region - Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 240 Pages | 商品交期: 1-5个工作天内

价格

全球核酸治疗药的CDMO的市场规模，2022年达到38亿8,000万美元，预计2033年达141亿9,000万美元，在预测期间的2023年～2033年预计以12.55％的年复合成长率成长。

由于治疗慢性疾病和遗传性疾病对核酸治疗药的需求扩大，CDMO(开发、受託製造厂商)的核酸製造的进步，核酸治疗药的FDA核准增加，CDMO製造单位的扩大的投资扩大等要素，牵引这个市场。

本报告提供全球核酸治疗药的CDMO市场相关调查，市场概要，以及化学合成各方法，各产品，各技术，各终端用户，各地区的趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 市场

  • 全球市场预测
  • 产业预测
  • COVID-19对全球核酸治疗药的CDMO的影响
  • 目前核酸治疗用CDMO的形势
  • 治疗的核酸重要的使用
  • 治疗用被合成的核酸的类型
  • 商务动态

第2章 全球核酸治疗药的CDMO市场(各化学合成法)

  • 机会评估
  • 成长占有率矩阵
  • 固相寡核甘酸合成(SPOS)
  • 液相寡核甘酸合成(LPOS)

第3章 全球核酸治疗药的CDMO市场(各产品)

  • 机会评估
  • 成长占有率矩阵
    • 标准核酸
    • 微规模核酸
    • 大规模核酸
    • 自订核酸
    • 修饰核酸
    • 底层涂料
    • 探针
    • 其他核酸
    • 其他服务

第4章 全球核酸治疗药的CDMO市场(各技术)

  • 机会评估
  • 成长占有率矩阵
  • 管柱为基础的方法
  • 微阵列为基础的方法

第5章 全球核酸治疗药的CDMO市场(各终端用户)

  • 机会评估
  • 成长占有率矩阵
  • 製药公司
  • 学术机构
  • 诊断检验室

第6章 全球核酸治疗药的CDMO市场(各地区)

  • 北美
  • 欧洲
  • 亚太地区
  • 其他地区

第7章 市场-竞争基准和企业简介

  • 竞争基准
  • 企业简介
    • Agilent Technologies, Inc.
    • AGC Biologics
    • Asymchem Inc.
    • BACHEM
    • BioCina
    • CMIC HOLDINGS Co., Ltd.
    • Codexis, Inc.
    • Danaher Corporation
    • Eurofins Scientific
    • GeneOne Life Science
    • Kaneka Corporation
    • LGC Science Group Holdings Limited
    • Maravai LifeSciences Holdings, Inc.
    • Merck KGaA
    • Nippon Shkubai Co., Ltd
    • ST Pharm
    • Thermo Fisher Scientific Inc.
Product Code: BHP1097SB

“Global Nucleic Acid Therapeutics CDMO Market to Reach $14.19 Billion by 2033.”

Intro on Nucleic Acid Therapeutics CDMO

The global nucleic acid therapeutics CDMO market was valued at $3.88 billion in 2022 and is expected to reach $14.19 billion by 2033, growing at a CAGR of 12.55% during the forecast period 2023-2033. The key factors driving the growth of the global nucleic acid therapeutics CDMO market include the growing demand for nucleic acid therapeutics applications to treat chronic and genetic diseases, manufacturing advancement for producing nucleic acid by CDMO (a contract development and manufacturing organization), increasing FDA (Food and Drug Administration) approvals of nucleic acid therapeutics, and increasing investment for the expansion of CDMO manufacturing units.

Market Introduction

CDMO: An organization that offers services including medication development, manufacturing, and pharmaceutical packaging that incorporates serialization and aggregation is known as a contract development and manufacturing organization or a CDMO. Based on their designs, formulas, and specifications or those of their clients, these businesses offer support services to several businesses.

Therapeutic Nucleic Acid: According to the National Centre for Biotechnology Information (NCBI), therapeutic nucleic acids (TNAs) are a subset of nucleic acids that are closely related compounds used to cure disease through the sequence-specific recognition of endogenous nucleic acids. The therapeutic use of nucleic acids can be broadly divided into two categories, i.e., DNA therapies (including gene therapy, DNA aptamers, and antisense oligonucleotides) and RNA therapeutics (micro RNAs, short interfering RNAs, ribozymes, RNA decoys, and circular RNAs).

Nucleic Acid Therapeutics CDMO Market: According to BIS Research, the nucleic acid therapeutics CDMO market refers to the products and services provided by CDMO companies for the manufacturing of nucleic acid therapeutics. These therapeutics can be produced by either CDMO companies or pharmaceutical companies.

Impact

Nucleic Acid Therapeutics has made an impact in the following ways:

Nucleic acids in cancer therapy- A flexible framework to comprehend and treat complicated genetic illnesses like cancer has been made possible by significant advancements in the field of RNA therapies. For instance, RNA interference (RNAi) enables the ability to silence specific genes that are responsible for the disease or that encourage it. For cancer immunotherapy, on the other hand, mRNA medicines can encode tumor-associated antigens. This section gives a general review of nucleic acid therapies, mostly for the treatment of cancer.

Nucleic acids therapeutics for combating infectious disease- Millions of people around the world lose their lives to infectious diseases each year, posing a serious threat to public health. Millions of people have died, specifically from the COVID-19 pandemic brought on by the brand-new SARS-CoV-2 coronavirus. The creation of vaccines has significantly aided in the control and prevention of infectious diseases and annually saves thousands of lives. Smallpox has been completely eradicated thanks to extensive vaccination use, but cases of several infectious diseases have increased.

RNA therapeutics for lung disorders - Recently, new polymeric complexes and cationic LNPs were used to transfer nucleic acids to the lungs. The lungs are easily accessible for localized drug administration by inhalation, even though these methods have started to develop targeting the lungs with the systemic distribution of nucleic acids. The three main techniques for pulmonary medication administration are Dry powder inhalers and pressurized metered-dose inhalers (pMDIs) (DPIs),

Nucleic acid therapeutics for ocular diseases- The first clinical uses of nucleic acid treatments were for the treatment of nervous system disorders, which frequently take the form of uncommon hereditary diseases. The creation of nucleic acid therapies offers an exciting case study in eye diseases. The developed and specialized cells that make up the retina normally serve as the tissue of interest in the eye as an extension of the central nervous system (CNS).

Nucleic acid therapeutics for neuromuscular diseases- Beyond the protected immunological environment of the inner eye, scientists have considered using nucleic acids to treat a variety of hereditary nervous system illnesses. Recent research has concentrated on creating therapies that simultaneously decrease aberrant splice variants of critical genes and introduce a necessary protein using gene therapy. Unfortunately, some neurodegenerative diseases can cause neuronal loss and muscular weakening.

Impact of COVID-19

The COVID-19 pandemic had a low impact on the nucleic acid therapeutics contract development and manufacturing organization (CDMO) sector. The demand for nucleic acid-based COVID-19 vaccines and therapies has led to an increased demand for CDMO services. Many CDMOs have experienced an uptick in orders for services such as nucleic acid synthesis, formulation, and manufacturing of viral vectors.

The future impact of COVID-19 on the demand and supply across the global nucleic acid therapeutics CDMO market depends on the abilities of stakeholders to withstand unforeseeable scenarios in the future. The intensity of impact due to COVID-19 in the future will depend on the current efforts being made by companies to equip their supply chains with the necessary components and processes to remain responsive.

Market Segmentation:

Segmentation 1: by Product Type

  • Standard Nucleic Acid
  • Micro-Scale Nucleic Acid
  • Large-scale nucleic acid
  • Custom Nucleic Acid
  • Modified Nucleic Acid
  • Primers
  • Probes
  • Other Nucleic Acid
  • Other Services

Standard Nucleic Acid to Continue Dominating the Nucleic Acid Therapeutics CDMO Market (by Products)

Products comprise standard nucleic acid, micro-scale nucleic acid, custom nucleic acid, modified nucleic acid, primers, probes, other nucleic acid, and other services.

Standard nucleic acid: Standard nucleic acids refer to naturally occurring nucleic acids that have a fixed basic structure without any modifications. These nucleic acids are in high demand for the production of various therapies associated with them. They form the foundation for the development of several biotechnology products and treatments in the healthcare industry. By using standard nucleic acids, researchers can better understand the natural functions of these molecules and develop effective treatments for various genetic disorders and diseases.

Micro-scale nucleic acid: Micro-scale nucleic acid refers to small fragments of DNA or RNA molecules that are typically less than 50 base pairs in length. These fragments are used in a variety of research applications, including PCR (polymerase chain reaction) amplification, sequencing, and gene expression analysis. The use of micro-scale nucleic acids allows for highly specific and sensitive detection of genetic material in samples, which is important for many applications in the fields of biotechnology, medicine, and agriculture. The ability to work with micro-scale nucleic acids is also essential for the development of new diagnostic tools and therapies that target specific genetic markers associated with the disease.

Large-scale nucleic acid: Large-scale nucleic acid production is a critical component of the global nucleic acid therapeutics CDMO industry, enabling the synthesis, purification, and characterization of nucleic acids at a commercial scale to meet the increasing demand for gene therapies and RNA-based therapeutics. It supports the advancement of precision medicine worldwide by delivering high-quality nucleic acids for therapeutic use, driving the development of innovative nucleic acid therapies for patients globally.

Custom nucleic acid: Custom nucleic acid refers to synthetic DNA or RNA molecules that are designed to have specific sequences and properties based on the researcher's needs. These sequences can be designed to match specific genes, mutations, or other genetic markers of interest, making them valuable tools for a variety of research applications, such as gene editing, gene therapy, and synthetic biology. Custom nucleic acids can be produced using various techniques, including chemical synthesis and gene synthesis, and can be modified with different functional groups and labels to enable specific interactions and detection.

Modified nucleic acid: Modified nucleic acids, also known as "clickmers" or xeno nucleic acids, can be easily adapted with almost any azide-bearing functional group through copper-catalyzed azide-alkyne cycloaddition. These modifications allow the incorporation of large chemical moieties, such as long carbohydrate chains and polycyclic compounds, which are usually incompatible with polymerase-mediated evolution methods. The resulting modular nucleic acid templates have various applications in gene therapy, molecular diagnostics, and gene editing, providing improved efficiency, specificity, and safety for these technologies. Additionally, chemical modifications can alter the properties of nucleic acids, such as stability and resistance to enzymatic degradation, making them valuable tools in many fields.

Primers: Primers are short, single-stranded DNA or RNA molecules that are used as starting points for DNA synthesis. They serve as complementary sequences to the template DNA or RNA strand and are essential components in several molecular biology techniques, including polymerase chain reaction (PCR), quantitative PCR (qPCR), and DNA sequencing. Primers are designed to be specific to the target sequence of interest, allowing for the amplification or detection of a particular gene or genetic marker. Accurate primer design is critical for the success of these techniques, as it can affect the specificity, sensitivity, and reproducibility of the results.

Probes: Probes are short, single-stranded DNA or RNA molecules that are used to detect and quantify specific nucleic acid sequences in a sample. They are designed to be complementary to the target sequence and are labeled with a detectable signal, such as a fluorescent or radioactive label. Probes are widely used in molecular biology techniques, such as PCR, qPCR, and DNA sequencing, and are valuable tools for disease diagnosis, genetic testing, and research. Accurate probe design is crucial for achieving high sensitivity and specificity in nucleic acid detection and quantification.

Other nucleic acid: The other nucleic acid category of the product involved within the global nucleic acid therapeutics CDMO market comprises products/services, including DNA origami reagents, WellRED Oligos, next-generation sequencing oligos, custom-locked nucleic acid oligonucleotides, antisense oligonucleotides, single-stranded DNA Extremer, double-stranded DNA Extremer and CRISPR RNA Synthesis, among others.

Other services: The other services segment under the products offered within the global nucleic acid therapeutics CDMO market includes services such as chemical development, analytical services, qualification and validation services, validation services, stability testing, and stability studies

Segmentation 2: by Technology

  • Column-Based Method
  • Microarray-Based Method

Column-Based Method to Register Maximum Share in the Market

Column-Based Method: The column-based technology for oligonucleotide synthesis, which involves the use of solid-phase phosphoramidite chemistry, has been a traditional method for synthesizing oligonucleotides. This technique utilizes separate columns that enable the iterative addition of nucleotides on the controlled-porosity glass beads (CPG) matrix in a programmable manner, with reagents being pumped through the columns. This results in the synthesis of one sequence per column. With commercially available column-based oligo synthesizers, it is possible to synthesize 96-768 oligonucleotides, each containing 10 nmol to 2 μmol simultaneously. These oligonucleotides have been utilized in several studies as modules for DNA constructions by assembly methods.

Microarray-Based Method: The microarray-based oligonucleotide synthesis method involves in-situ synthesis or deposition of pre-synthesized oligonucleotides that range in size from 25- to 60-mers. Thousands of distinct features on the microarray chips enable the simultaneous synthesis of unique oligonucleotide sequences, with one per chip feature. The resulting product is a pool of sequences containing every oligonucleotide synthesized on the array, which requires further processing to isolate the desired oligonucleotide sequences for subsequent gene synthesis.

Segmentation 3: by Disease Type

  • Genetic Disease
  • Infectious Disease

Genetic Disease segment: Highest share in the market due to the high number of FDA approvals of nucleic acid drugs treating genetic diseases.

Genetic Disease: Nucleic acid therapeutics are a diverse range of sequence-programmable medications that provide an effective and clinically practical method to modify expression or fix genetic abnormalities that cause disease with the help of intuitive engagement with genome sequences made possible by nucleic acid therapies, many diseases can now be directly targeted at their genetic source.

Infectious Disease: Nucleic acid therapeutics for infectious diseases has demonstrated considerable promise. They offer a fresh method to fight infections since they can target certain viruses by interfering with their genetic material or by blocking crucial viral proteins.

Segmentation 4: By Chemical Synthesis Method

  • Solid-Phase Oligonucleotide Synthesis
  • Liquid-Phase Oligonucleotide Synthesis

Solid-Phase Oligonucleotide Synthesis to Dominate the Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method)

Solid-Phase Oligonucleotide Synthesis: Solid-phase oligonucleotide synthesis is a highly efficient and widely used method for synthesizing oligonucleotides. This technique involves the use of solid support held between filters within columns that allow reagents and solvents to pass through freely. Traditional solid-phase synthesis uses polymer or specialized glass beads that are not affected by reaction conditions. Solid-phase synthesis yields high-purity products rapidly, and the entire process can be easily automated and controlled using computer systems, making it cost-effective. Custom oligonucleotide production benefits significantly from solid-phase synthesis, allowing the rapid and cost-effective synthesis of highly pure oligonucleotides tailored to specific research or therapeutic needs.

Liquid-Phase Oligonucleotide Synthesis: Liquid-phase oligonucleotide synthesis is a method for synthesizing oligonucleotides on a large scale that utilizes soluble polymer support. The technique requires three reaction steps and 4-5 precipitation steps per nucleotide addition, making it more time-consuming and labor-intensive than solid-phase synthesis. However, LPOS offers several advantages over solid-phase syntheses, such as easy purification of the final product by removing interfering compounds through precipitation or membrane filtration.

Segmentation 5: By End User

  • Pharmaceutical Companies
  • Academic Research Institute
  • Diagnostic Laboratories

Pharmaceutical companies have been dominating the nucleic acid therapeutics CDMO market for a long time and hold the largest market share currently, followed by academic research institutes.

Segmentation 6: by Region

  • North America - U.S., Canada
  • Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe
  • Asia-Pacific - China, Japan, India, Australia, and Rest-of-Asia-Pacific
  • Rest-of-the-World

North America has witnessed the increase in investment for the production of nucleic acid therapeutics by CDMO. Furthermore, the presence of several established companies and startups, as well as the FDA approvals, resulted in this region holding the maximum share in the global nucleic acid therapeutics CDMO market in 2022, followed by Europe.

Recent Developments in the Nucleic acid therapeutics CDMO Market

  • In June 2021, Danaher Corporation acquired Aldeveron for $9.6 billion. Through this acquisition, the company will expand its manufacturing capacity in plasmid DNA and mRNA.
  • In January 2023, Agilent Technologies, Inc. invested $725 million to increase its manufacturing capacity for therapeutic nucleic acids.
  • In March 2022, IMM, a partner of VGXI, has recently announced that it received a $12 million grant from the National Institutes of Health (NIH) to support the Phase 1 clinical trial of a DNA vaccine aimed at preventing Alzheimer's disease. The vaccine will be manufactured using VGXI's expertise in contract manufacturing of DNA plasmids for human clinical trials, produced in accordance with GMP standards.
  • In April 2022, BACHEM partnered with Eli Lilly and Company to develop and manufacture active pharmaceutical ingredients based on oligonucleotides, a rising new class of complex molecules.
  • In September 2021, AGC Biologics expanded the company's Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.
  • In August 2022, Codexis and Molecular Assemblies announced the execution of a commercial license and enzyme supply agreement for an optimized TdT enzyme for enzymatic DNA synthesis.
  • In June 2020, OliX Pharmaceuticals, Inc. partnered with LGC Biosearch Technologies Inc. to scale up the production of OliX's OLX301D therapeutic candidate.

Demand - Drivers and Limitations

Market Demand Drivers:

Growing demand for nucleic acid therapeutics applications to treat chronic and genetic diseases: There is a growing demand for nucleic acid therapeutics due to their potential in treating chronic and genetic diseases. Nucleic acids, such as DNA and RNA, are essential molecules that play a key role in the regulation of gene expression and protein synthesis in cells. In recent years, researchers have made significant progress in developing new techniques for the delivery of nucleic acids to specific cells and tissues in the body, which has opened new avenues for the development of targeted therapeutics.

Increasing FDA or European Medicines Agency (EMA) approvals of nucleic acid Therapeutics: Nucleic acid therapeutics, including RNA and DNA-based treatments, have seen a significant increase in approval and development in recent years. This is largely due to advances in technology and the understanding of the genetic mechanisms that underlie many diseases. For instance, nucleic acid therapeutic that has gained approval is Onpattro (patisiran), which is a small interfering RNA (siRNA) therapy for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR). This was the first RNA interference (RNAi) therapy to receive approval from the U.S. FDA in 2018.

Advancements in manufacturing units for producing nucleic acid by CDMO: There have been several recent advancements in manufacturing technology that CDMOs can utilize to improve efficiency and reduce costs.

One such advancement is the use of continuous manufacturing processes. This method involves running reactions in a continuous flow rather than batch processing, which can be time-consuming and requires a significant amount of equipment. Continuous manufacturing allows for faster processing times and reduces the need for large amounts of starting materials and reagents. Another advancement is the use of automated systems for nucleic acid purification and analysis. Automation can help to reduce errors and increase accuracy, as well as improve efficiency and reduce costs. These systems can also be used to improve the scalability of nucleic acid production, making it easier for CDMOs to produce large quantities of nucleic acids for research or commercial use.

Market Restraints:

Substantial variation in nucleic acid leads to complications in therapeutic classification: The large variation in nucleic acids, specifically in DNA and RNA sequences, can indeed make therapeutic classification difficult. This is because the specificity of a drug to a particular sequence or target is critical for its effectiveness and safety. However, because of the vast diversity of nucleic acid sequences, it can be challenging to develop a drug that targets a specific sequence or gene without affecting other unrelated sequences. Several forms of nucleic acid medications have different molecular weights (ranging from 2,400 to 16,000 amu), sizes (single or double-stranded), numbers of nucleotides, and negative charges. As the drug molecules interact with the target mRNAs, cells, and tissues, these variations lead to a wide range of different modes of action.

Lack of expertise in developing nucleic acid therapeutics: the production of peptides and nucleic acids differs significantly. Large amounts of solvents and reagents are used during the synthesis in flow-through columns; thus, the facility infrastructure will be increased adequately. Moreover, because oligonucleotides are extremely water-soluble and negatively charged, aqueous solutions must be handled during the entire downstream process. The oligonucleotide APIs, in particular double-stranded molecules, are also much larger than peptides and provide difficulties from an analytical standpoint.

Market Opportunities:

Continued Research and Development Activities for Manufacturing Innovative Nucleic Acid Therapeutics Forcing Pharmaceutical Companies to Expand their Businesses: Nucleic acid therapeutics, including RNA-based therapies such as messenger RNA (mRNA) vaccines and small interfering RNA (siRNA) drugs, are a rapidly growing area of pharmaceutical research and development. These therapies have the potential to treat a wide range of diseases, including genetic disorders, infectious diseases, and cancer, by targeting specific genes and proteins.

Pharmaceutical Firms Becoming More Outsourcing-Oriented: The trend of pharmaceutical firms becoming more outsourcing-oriented can be an opportunity for contract development and manufacturing organizations (CDMOs). Pharmaceutical companies are increasingly looking to outsource various aspects of their operations to external partners, including drug development, manufacturing, and clinical trials. This trend has been driven by factors such as cost reduction, increasing complexity of drug development, and the need for specialized expertise.

How can this report add value to an organization?

  • Product/Innovation Strategy: The global nucleic acid therapeutics CDMO market has been extensively segmented based on various categories, such as product, chemical synthesis method, disease type, technology, and end users. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
  • Growth/Marketing Strategy: Synergistic activities and product business expansion accounted for the maximum number of key developments, i.e., nearly 38.54% of the total developments in the global nucleic acid therapeutics CDMO market, as of February 2023.
  • Competitive Strategy: The global nucleic acid therapeutics CDMO market is competitive, with around four key players accounting for a large market share. Key players in the global nucleic acid therapeutics CDMO market analysed and profiled in the study involve established players that offer various kinds of nucleic acid therapeutics CDMO products.

The global nucleic acid therapeutics CDMO market has witnessed several investments for the expansion of CDMO manufacturing units by the market players. The expansion is aimed at increasing the manufacturing capacity. To meet the growing demand for their services, CDMOs are expanding their manufacturing units and investing in new technologies. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

Key Companies Profiled:

  • Agilent Technologies, Inc.
  • AGC Biologics
  • Asymchem Inc.
  • BACHEM
  • BioCina
  • Catalent, Inc
  • CMIC HOLDINGS Co., Ltd.
  • Codexis, Inc.
  • Danaher Corporation
  • Eurofins Scientific
  • GeneOne Life Science
  • Kaneka Corporation
  • LGC Science Group Holdings Limited
  • Maravai LifeSciences Holdings, Inc.
  • Merck KGaA
  • Nippon Shkubai Co., Ltd
  • Nitto Group
  • ST Pharm
  • Thermo Fisher Scientific Inc.

Table of Contents

1 Market

  • 1.1 Global Market Outlook
    • 1.1.1 Market Overview
    • 1.1.2 Product Definition
    • 1.1.3 Inclusion and Exclusion Criteria
    • 1.1.4 Key Findings
  • 1.2 Industry Outlook
    • 1.2.1 Key Trends
      • 1.2.1.1 Significant Number of Collaborations among Market Players
      • 1.2.1.2 Increasing Investment for Expansion of Nucleic Acid Therapeutics CDMO Manufacturing Units
      • 1.2.1.3 CDMOs Shifting their Business Strategy in Response to a Changing Environment
    • 1.2.2 Opportunity Assessment
    • 1.2.3 Patent Analysis
      • 1.2.3.1 Awaited Technological Developments
      • 1.2.3.2 Patent Filing Trend (by Country)
      • 1.2.3.3 Patent Filing Trend (by Year)
    • 1.2.4 Production Capability
    • 1.2.5 Preferred Techniques By CDMO
      • 1.2.5.1 Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
      • 1.2.5.2 Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
      • 1.2.5.3 Preferred Techniques by CDMOs for Nucleic Acid Purification
    • 1.2.6 Factors Considered While Outsourcing To CDMO.
    • 1.2.7 Regulatory Framework
  • 1.3 Impact of COVID-19 on the Global Nucleic Acid Therapeutics CDMO
    • 1.3.1 Pre-COVID-19 Phase
    • 1.3.2 During COVID-19
    • 1.3.3 Post-COVID-19 Phase
      • 1.3.3.1 Impact on Demand and Supply
  • 1.4 Current Nucleic Acid Therapeutic CDMOs Landscape
  • 1.5 Significant Usage of Nucleic Acid in Therapeutics
  • 1.6 Types of Nucleic Acid Synthesized for Therapeutics
    • 1.6.1 Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
    • 1.6.2 RNA Interference (RNAi) and Short Interfering RNAs (siRNAs)
    • 1.6.3 MicroRNAs (miRNAs)
    • 1.6.4 RNA Aptamers and RNA Decoys
    • 1.6.5 Ribozymes
    • 1.6.6 Circular RNAs
  • 1.7 Business Dynamics
    • 1.7.1 Impact Analysis
    • 1.7.2 Business Drivers
      • 1.7.2.1 Growing Demand for Nucleic Acid Therapeutics Application to Treat Chronic and Genetic Diseases
      • 1.7.2.2 Increasing FDA or European Medicines Agency (EMA) Approvals of Nucleic Acid Therapeutics
      • 1.7.2.3 Advancements in Manufacturing Units for Producing Nucleic Acid by CDMOs
    • 1.7.3 Business Restraints
      • 1.7.3.1 Substantial Variations in Nucleic Acid Leading to Complications in Therapeutic Classification
      • 1.7.3.2 Lack of Expertise in Developing Nucleic Acid Therapeutic
    • 1.7.4 Business Opportunities
      • 1.7.4.1 Continued Research and Development Activities for Manufacturing Innovative Nucleic Acid Therapeutics Forcing Pharmaceutical Companies to Expand their Businesses.
      • 1.7.4.2 Pharmaceutical Firms Becoming More Outsourcing-Oriented

2 Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method)

  • 2.1 Opportunity Assessment
  • 2.2 Growth-Share Matrix
  • 2.3 Solid-Phase Oligonucleotide Synthesis (SPOS)
  • 2.4 Liquid-Phase Oligonucleotide Synthesis (LPOS)

3 Global Nucleic Acid Therapeutics CDMO Market (by Product)

  • 3.1 Opportunity Assessment
  • 3.2 Growth-Share Matrix
    • 3.2.1 Standard Nucleic Acid
    • 3.2.2 Micro-Scale Nucleic Acid
    • 3.2.3 Large-Scale Nucleic Acid
    • 3.2.4 Custom Nucleic Acid
    • 3.2.5 Modified Nucleic Acid
    • 3.2.6 Primers
    • 3.2.7 Probes
    • 3.2.8 Other Nucleic Acid
    • 3.2.9 Other Services

4 Global Nucleic Acid Therapeutics CDMO Market (by Technology)

  • 4.1 Opportunity Assessment
  • 4.2 Growth-Share Matrix
  • 4.3 Column-Based Method
  • 4.4 Microarray-Based Method

5 Global Nucleic Acid Therapeutics CDMO Market (by Disease Type)

  • 5.1 Opportunity Assessment
  • 5.2 Growth-Share Matrix
  • 5.3 Genetic disease
  • 5.4 Infectious disease

6 Global Nucleic Acid Therapeutics CDMO Market (by End Users)

  • 6.1 Opportunity Assessment
  • 6.2 Growth-Share Matrix
  • 6.3 Pharmaceutical Companies
  • 6.4 Academic Institutions
  • 6.5 Diagnostic Laboratories

7 Global Nucleic Acid Therapeutics CDMO Market (by Region)

  • 7.1 North America Nucleic Acid Therapeutics CDMO Market
    • 7.1.1 Key Findings
    • 7.1.2 Market Dynamics
      • 7.1.2.1 Impact Analysis
    • 7.1.3 Market Sizing and Forecast
      • 7.1.3.1 North America Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 7.1.3.2 North America Nucleic Acid Therapeutics CDMO Market (by Country)
        • 7.1.3.2.1 U.S.
          • 7.1.3.2.1.1 U.S. Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 7.1.3.2.2 Canada
          • 7.1.3.2.2.1 Canada Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
  • 7.2 Europe Nucleic Acid Therapeutics CDMO Market
    • 7.2.1 Key Findings
    • 7.2.2 Market Dynamics
      • 7.2.2.1 Impact Analysis
    • 7.2.3 Market Sizing and Forecast
      • 7.2.3.1 Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 7.2.3.2 Europe Nucleic Acid Therapeutics CDMO Market (by Country)
        • 7.2.3.2.1 Germany
          • 7.2.3.2.1.1 Germany Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 7.2.3.2.2 U.K.
          • 7.2.3.2.2.1 U.K. Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 7.2.3.2.3 France
          • 7.2.3.2.3.1 France Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 7.2.3.2.4 Spain
          • 7.2.3.2.4.1 Spain Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 7.2.3.2.5 Italy
          • 7.2.3.2.5.1 Italy Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 7.2.3.2.6 Rest-of-Europe
          • 7.2.3.2.6.1 Rest-of-Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
  • 7.3 Asia-Pacific Nucleic Acid Therapeutics CDMO Market
    • 7.3.1 Key Findings
    • 7.3.2 Market Dynamics
      • 7.3.2.1 Impact Analysis
    • 7.3.3 Market Sizing and Forecast
      • 7.3.3.1 Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 7.3.3.2 Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Country)
        • 7.3.3.2.1 Japan
          • 7.3.3.2.1.1 Japan Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 7.3.3.2.2 China
          • 7.3.3.2.2.1 China Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 7.3.3.2.3 India
          • 7.3.3.2.3.1 India Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 7.3.3.2.4 Australia
          • 7.3.3.2.4.1 Australia Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
        • 7.3.3.2.5 Rest-of-Asia-Pacific
          • 7.3.3.2.5.1 Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
  • 7.4 Rest-of-the-World Nucleic Acid Therapeutics CDMO Market
    • 7.4.1 Key Findings
    • 7.4.2 Market Dynamics
      • 7.4.2.1 Impact Analysis
    • 7.4.3 Market Sizing and Forecast
        • 7.4.3.1.1 Rest-of-the-World Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)

8 Markets - Competitive Benchmarking & Company Profiles

  • 8.1 Competitive Benchmarking
    • 8.1.1 Key Strategies and Developments
      • 8.1.1.1 Funding Activities
      • 8.1.1.2 New Offerings
      • 8.1.1.3 Mergers and Acquisitions
      • 8.1.1.4 Partnerships and Collaborations
      • 8.1.1.5 Business Expansions
      • 8.1.1.6 Regulatory and Legal Activities
    • 8.1.2 Market Share Analysis
    • 8.1.3 Visual Graphics of Key Companies
  • 8.2 Company Profile
    • 8.2.1 Agilent Technologies, Inc.
      • 8.2.1.1 Company Overview
      • 8.2.1.2 Role of Agilent Technologies, Inc. in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.1.3 Financials
      • 8.2.1.4 Recent Developments
      • 8.2.1.5 Analyst Perspective
    • 8.2.2 AGC Biologics
      • 8.2.2.1 Company Overview
      • 8.2.2.2 Role of AGC Biologics in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.2.3 Financials
      • 8.2.2.4 Recent Developments
      • 8.2.2.5 Analyst Perspective
    • 8.2.3 Asymchem Inc.
      • 8.2.3.1 Company Overview
      • 8.2.3.2 Role of Asymchem Inc. in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.3.3 Financials
      • 8.2.3.4 Recent Developments
      • 8.2.3.5 Analyst Perspective
    • 8.2.4 BACHEM
      • 8.2.4.1 Company Overview
      • 8.2.4.2 Role of BACHEM in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.4.3 Financials
      • 8.2.4.4 Recent Developments
      • 8.2.4.5 Analyst Perspective
    • 8.2.5 BioCina
      • 8.2.5.1 Company Overview
      • 8.2.5.2 Role of BioCina in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.5.3 Recent Developments
      • 8.2.5.4 Analyst Perspective
    • 8.2.6 Catalent, Inc
      • 8.2.6.1 Company Overview
      • 8.2.6.2 Role of Catalent, Inc in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.6.3 Financials
      • 8.2.6.4 Recent Developments
      • 8.2.6.5 Analyst Perspective
    • 8.2.7 CMIC HOLDINGS Co., Ltd.
      • 8.2.7.1 Company Overview
      • 8.2.7.2 Role of CMIC HOLDINGS Co., Ltd. In the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.7.3 Financials
      • 8.2.7.4 Analyst Perspective
    • 8.2.8 Codexis, Inc.
      • 8.2.8.1 Company Overview
      • 8.2.8.2 Role of Codexis, Inc. in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.8.3 Financials
      • 8.2.8.4 Recent Developments
      • 8.2.8.5 Analyst Perspective
    • 8.2.9 Danaher Corporation
      • 8.2.9.1 Company Overview
      • 8.2.9.2 Role of Danaher Corporation in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.9.3 Financials
      • 8.2.9.4 Recent Developments
      • 8.2.9.5 Analyst Perspective
    • 8.2.10 Eurofins Scientific
      • 8.2.10.1 Company Overview
      • 8.2.10.2 Role of Eurofins Scientific in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.10.3 Financials
      • 8.2.10.4 Recent Developments
      • 8.2.10.5 Analyst Perspective
    • 8.2.11 GeneOne Life Science
      • 8.2.11.1 Company Overview
      • 8.2.11.2 Role of GeneOne Life Science in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.11.3 Recent Developments
      • 8.2.11.4 Analyst Perspective
    • 8.2.12 Kaneka Corporation
      • 8.2.12.1 Company Overview
      • 8.2.12.2 Role of Kaneka Corporation in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.12.3 Financials
      • 8.2.12.4 Recent Developments
      • 8.2.12.5 Analyst Perspective
    • 8.2.13 LGC Science Group Holdings Limited
      • 8.2.13.1 Company Overview
      • 8.2.13.2 Role of LGC Science Group Holdings Limited in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.13.3 Recent Developments
      • 8.2.13.4 Analyst Perspective
    • 8.2.14 Maravai LifeSciences Holdings, Inc.
      • 8.2.14.1 Company Overview
      • 8.2.14.2 Role of Maravai LifeSciences Holdings, Inc. in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.14.3 Financials
      • 8.2.14.4 Recent Developments
      • 8.2.14.5 Analyst Perspective
    • 8.2.15 Merck KGaA
      • 8.2.15.1 Company Overview
      • 8.2.15.2 Role of Merck KGaA in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.15.3 Financials
      • 8.2.15.4 Recent Developments
      • 8.2.15.5 Analyst Perspective
    • 8.2.16 Nippon Shkubai Co., Ltd
      • 8.2.16.1 Company Overview
      • 8.2.16.2 Role of Nippon Shokubai Co., Ltd in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.16.3 Financials
      • 8.2.16.4 Analyst Perspective
    • 8.2.17 Nitto Group
      • 8.2.17.1 Company Overview
      • 8.2.17.2 Role of Nitto Group in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.17.3 Financials
      • 8.2.17.4 Recent Developments
      • 8.2.17.5 Analyst Perspective
    • 8.2.18 ST Pharm
      • 8.2.18.1 Company Overview
      • 8.2.18.2 Role of ST Pharm in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.18.3 Financials
      • 8.2.18.4 Recent Developments
      • 8.2.18.5 Analyst Perspective
    • 8.2.19 Thermo Fisher Scientific Inc.
      • 8.2.19.1 Company Overview
      • 8.2.19.2 Role of Thermo Fisher Scientific Inc. in the Global Nucleic Acid Therapeutics CDMO Market
      • 8.2.19.3 Financials
      • 8.2.19.4 Analyst Perspective

List of Figures

  • Figure 1: Services Offered by CDMOs
  • Figure 2: Global Nucleic Acid Therapeutics CDMO Market, Impact Analysis
  • Figure 3: Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method), % Share, 2022 and 2033
  • Figure 4: Global Nucleic Acid Therapeutics CDMO Market (by Region), $Billion, 2022 and 2033
  • Figure 5: Global Nucleic Acid Therapeutics CDMO Market Segmentation
  • Figure 6: Global Nucleic Acid Therapeutics CDMO Market: Research Methodology
  • Figure 7: Primary Research Methodology
  • Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 9: Top-Down Approach (Segment-Wise Analysis)
  • Figure 10: Significant Number of Collaborations among Market Players in Global Nucleic Acid Therapeutics CDMO Market, 2019-2023
  • Figure 11: Core CDMO Services
  • Figure 12: Global Nucleic Acid Therapeutics CDMO Market Key Trends, Market Shift, 2022-2033
  • Figure 13: Global Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Country), January 2018-January 2023
  • Figure 14: Global Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Year), January 2018-December2022
  • Figure 15: Synthesis Capabilities of Key Companies
  • Figure 16: Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
  • Figure 17: Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
  • Figure 18: Preferred Techniques by CDMOs for Nucleic Acid Purification
  • Figure 19: Factors considered while outsourcing to CDMO.
  • Figure 20: Global Nucleic Acid Therapeutics CDMO Market, Impact Analysis
  • Figure 21: Significant Increase in Sale of TEGSEDI and WAYLIVRA Drugs in $Million, 2018-2021
  • Figure 22: Significant Number of Nucleic Acid Drugs Approved by FDA or EMA in Global Nucleic Acid Therapeutics CDMO Market, 2018-2020
  • Figure 23: Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method)
  • Figure 24: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by Chemical Synthesis Method), $Billion, 2023-2033
  • Figure 25: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by Chemical Synthesis Method), 2022-2033
  • Figure 26: Advantages and Disadvantages of Solid-Phase Oligonucleotide Synthesis
  • Figure 27: Global Nucleic Acid Therapeutics CDMO Market (Solid-Phase Oligonucleotide Synthesis), $Billion, 2022-2033
  • Figure 28: Advantages and Disadvantages of Liquid-Phase Oligonucleotide Synthesis
  • Figure 29: Global Nucleic Acid Therapeutics CDMO Market (Liquid-Phase Oligonucleotide Synthesis), $Billion, 2022-2033
  • Figure 30: Global Nucleic Acid Therapeutics CDMO Market (by Product)
  • Figure 31: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by Product), $Billion, 2023-2033
  • Figure 32: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by Product), 2022-2033
  • Figure 33: Global Nucleic Acid Therapeutics CDMO Market (Standard Nucleic Acid), $Billion, 2022-2033
  • Figure 34: Global Nucleic Acid Therapeutics CDMO Market (Micro-Scale Nucleic Acid), $Billion, 2022-2033
  • Figure 35: Global Nucleic Acid Therapeutics CDMO Market (Large-Scale Nucleic Acid), $Billion, 2022-2033
  • Figure 36: Global Nucleic Acid Therapeutics CDMO Market (Custom Nucleic Acid), $Billion, 2022-2033
  • Figure 37: Global Nucleic Acid Therapeutics CDMO Market (Modified Nucleic Acid), $Billion, 2022-2033
  • Figure 38: Global Nucleic Acid Therapeutics CDMO Market (Primers), $Billion, 2022-2033
  • Figure 39: Global Nucleic Acid Therapeutics CDMO Market (Probes), $Billion, 2022-2033
  • Figure 40: Global Nucleic Acid Therapeutics CDMO Market (Other Nucleic Acid), $Billion, 2022-2033
  • Figure 41: Global Nucleic Acid Therapeutics CDMO Market (Other Services), $Billion, 2022-2033
  • Figure 42: Global Nucleic Acid Therapeutics CDMO Market (by Technology)
  • Figure 43: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by Technology), $Billion, 2023-2033
  • Figure 44: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by Technology), 2022-2033
  • Figure 45: Global Nucleic Acid Therapeutics CDMO Market (by Column-Based Method), $Billion, 2022-2033
  • Figure 46: Global Nucleic Acid Therapeutics CDMO Market (Microarray-Based Method), $Billion, 2022-2033
  • Figure 47: Global Nucleic Acid Therapeutics CDMO Market (by Disease Type)
  • Figure 48: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by Disease Type), $Billion, 2023-2033
  • Figure 49: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by Disease Type), 2022-2033
  • Figure 50: Global Nucleic Acid Therapeutics CDMO Market (Genetic disease), $Billion, 2022-2033
  • Figure 51: Global Nucleic Acid Therapeutics CDMO Market (Infectious disease), $Billion, 2022-2033
  • Figure 52: Global Nucleic Acid Therapeutics CDMO Market (by End User)
  • Figure 53: Global Nucleic Acid Therapeutics CDMO Market, Incremental Opportunity (by End User), $Billion, 2023-2033
  • Figure 54: Global Nucleic Acid Therapeutics CDMO Market, Growth-Share Matrix (by End User), 2022-2033
  • Figure 55: Global Nucleic Acid Therapeutics CDMO Market (Pharmaceutical Companies), $Billion, 2022-2033
  • Figure 56: Global Nucleic Acid Therapeutics CDMO Market (Academic Institutions), $Billion, 2022-2033
  • Figure 57: Global Nucleic Acid Therapeutics CDMO Market (Diagnostic Laboratories), $Billion, 2022-2033
  • Figure 58: Global Nucleic Acid Therapeutics CDMO Market Share (by Region), 2022-2033
  • Figure 59: North America Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 60: North America Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 61: North America Nucleic Acid Therapeutics CDMO Market (by Country), % Share, 2022 and 2033
  • Figure 62: U.S. Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 63: U.S. Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 64: Canada Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 65: Canada Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 66: Europe Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 67: Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 68: Europe Nucleic Acid Therapeutics CDMO Market (by Country), Share (%), 2022 and 2033
  • Figure 69: Germany Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 70: Germany Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 71: U.K. Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 72: U.K. Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 73: France Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 74: France Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 75: Spain Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 76: Spain Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 77: Italy Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 78: Italy Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 79: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 80: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 81: Incidence of Hematologic Malignancies, Asia, 2020 vs. 2040
  • Figure 82: Asia-Pacific Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 83: Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 84: Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Country), % Share, 2022 and 2033
  • Figure 85: Japan Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 86: Japan Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 87: China Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 88: China Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 89: India Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 90: India Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 91: Australia Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 92: Australia Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 93: Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 94: Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 95: Rest-of-the-World Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
  • Figure 96: Rest-of-the-World Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
  • Figure 97: Global Nucleic Acid Therapeutics CDMO Market, Number of Key Developments and Strategies, January 2018-February 2023
  • Figure 98: Funding Activities, January 2018-February 2023
  • Figure 99: New Offerings, January 2018-February 2023
  • Figure 100: Mergers and Acquisitions, January 2018-February 2023
  • Figure 101: Partnerships and Collaborations, January 2018-February 2023
  • Figure 102: Business Expansions, January 2018-February 2023
  • Figure 103: Regulatory and Legal Activities, January 2018-February 2023
  • Figure 104: Global Nucleic Acid Therapeutics CDMO Market, Company Revenue Share Analysis, $Billion, 2022
  • Figure 105: Some of the Active Players in the Nucleic Acid Therapeutics CDMO Market
  • Figure 106: Agilent Technologies, Inc: Product Portfolio
  • Figure 107: Agilent Technologies, Inc.: Overall Financials, $Million, 2020-2022
  • Figure 108: Agilent Technologies, Inc.: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 109: Agilent Technologies, Inc.: Net Revenue (by Region), $Million, 2020-2022
  • Figure 110: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2020-2022
  • Figure 111: AGC Biologics: Product Portfolio
  • Figure 112: AGC Biologics: Overall Financials, $Million, 2019-2021
  • Figure 113: AGC Biologics: Segment Revenues, $Million, 2019-2021
  • Figure 114: AGC Biologics: Net Revenue (by Region), $Million, 2020-2021
  • Figure 115: Asymchem Inc.: Product Portfolio
  • Figure 116: Asymchem Inc.: Overall Financials, $Million, 2021-2022
  • Figure 117: Asymchem Inc.: Net Revenue (by Segment), $Million, 2021-2022
  • Figure 118: Asymchem Inc.: Net Revenue (by Region), $Million, 2021-2022
  • Figure 119: Asymchem Inc.: R&D Expenditure, $Million, 2021-2022
  • Figure 120: BACHEM: Product Portfolio
  • Figure 121: BACHEM: Overall Financials, $Million, 2020-2022
  • Figure 122: BACHEM: Net Revenues (by Segment), $Million, 2020-2022
  • Figure 123: BACHEM: Net Revenue (by Region), $Million, 2020-2022
  • Figure 124: BACHEM: R&D Expenditure, $Million, 2020-2022
  • Figure 125: BioCina: Product Portfolio
  • Figure 126: Catalent, Inc: Product Portfolio
  • Figure 127: Catalent, Inc: Overall Financials, $Million, 2020-2022
  • Figure 128: Catalent, Inc: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 129: Catalent, Inc: Net Revenue (by region), $Million, 2020-2022
  • Figure 130: Catalent, Inc: R&D Expenditure, $Million, 2020-2022
  • Figure 131: CMIC HOLDINGS Co., Ltd.: Product Portfolio
  • Figure 132: CMIC HOLDINGS Co., Ltd.: Overall Financials, $Million, 2020-2022
  • Figure 133: CMIC HOLDINGS Co., Ltd.: Segment Revenues, $Million, 2020-2022
  • Figure 134: CMIC HOLDINGS Co., Ltd.: Net Revenue (by Region), $Million, 2020-2022
  • Figure 135: CMIC HOLDINGS Co., Ltd.: R&D Expenditure, $Million, 2020-2022
  • Figure 136: Codexis, Inc: Product Portfolio
  • Figure 137: Codexis, Inc: Overall Financials, $Million, 2020-2022
  • Figure 138: Codexis, Inc.: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 139: Codexis, Inc.: Net Revenue (by Region), $Million, 2020-2022
  • Figure 140: Codexis, Inc.: R&D Expenditure, $Million, 2020-2022
  • Figure 141: Danaher Corporation: Product Portfolio
  • Figure 142: Danaher Corporation: Overall Financials, $Million, 2020-2022
  • Figure 143: Danaher Corporation: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 144: Danaher Corporation: Net Revenue (by Region), $Million, 2020-2022
  • Figure 145: Danaher Corporation: R&D Expenditure, $Million, 2020-2022
  • Figure 146: Eurofins Scientific: Product Portfolio
  • Figure 147: Eurofins Scientific: Overall Financials, $Million, 2020-2022
  • Figure 148: Eurofins Scientific: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 149: Eurofins Scientific: Net Revenue (by Region), $Million, 2020-2022
  • Figure 150: VGXI, Inc.: Product Portfolio
  • Figure 151: Kaneka Corporation: Product Portfolio
  • Figure 152: Kaneka Corporation: Overall Financials, $Million, 2019-2021
  • Figure 153: Kaneka Corporation: Net Revenue (by Segment), $Million, 2019-2021
  • Figure 154: Kaneka Corporation: Net Revenue (by Region), $Million, 2019-2021
  • Figure 155: Kaneka Corporation: R&D Expenditure, $Million, 2019-2021
  • Figure 156: LGC Science Group Holdings Limited: Product Portfolio
  • Figure 157: LGC Science Group Holdings Limited: Overall Financials, $Million, 2020-2022
  • Figure 158: LGC Science Group Holdings Limited: Net Revenue (by Segment), $Million, 2021-2022
  • Figure 159: LGC Science Group Holdings Limited: Net Revenue (by Region), $Million, 2020-2022
  • Figure 160: LGC Science Group Holdings Limited: R&D Expenditure, $Million, 2020-2022
  • Figure 161: Maravai LifeSciences Holdings, Inc.: Product Portfolio
  • Figure 162: Maravai LifeSciences Holdings, Inc.: Overall Financials, $Million, 2020-2022
  • Figure 163: Maravai LifeSciences Holdings, Inc.: Segment Revenues, $Million, 2020-2022
  • Figure 164: Maravai LifeSciences Holdings, Inc.: Net Revenue (by Region), $Million, 2020-2022
  • Figure 165: Maravai LifeSciences Holdings, Inc: R&D Expenditure, $Million, 2020-2022
  • Figure 166: Merck KGaA: Product Portfolio
  • Figure 167: Merck KGaA: Overall Financials, $Million, 2020-2022
  • Figure 168: Merck KGaA: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 169: Merck KGaA: Net Revenue (by Region), $Million, 2020-2022
  • Figure 170: Merck KGaA: R&D Expenditure, $Million, 2020-2022
  • Figure 171: Nippon Shokubai Co., Ltd: Product Portfolio
  • Figure 172: Nippon Shokubai Co., Ltd: Overall Financials, $Million, 2019-2021
  • Figure 173: Nippon Shokubai Co., Ltd: Segment Revenues, $Million, 2019-2021
  • Figure 174: Nitto Group: Product Portfolio
  • Figure 175: Nitto Group: Overall Financials, $Million, 2019-2021
  • Figure 176: Nitto Group: Segment Revenues, $Million, 2019-2021
  • Figure 177: Nitto Group: Net Revenue (by region), $Million, 2019-2021
  • Figure 178: Nitto Group: R&D Expenditure, $Million, 2019-2021
  • Figure 179: ST Pharm: Product Portfolio
  • Figure 180: ST Pharm: Overall Financials, $Million, 2019-2021
  • Figure 181: ST Pharm: Net Revenue (by Segment), $Million, 2019-2021
  • Figure 182: Thermo Fisher Scientific Inc.: Product Portfolio
  • Figure 183: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
  • Figure 184: Thermo Fisher Scientific Inc.: Net Revenue (by Segment), $Million, 2020-2022
  • Figure 185: Thermo Fisher Scientific Inc.: Net Revenue (by Region), $Million, 2020-2022
  • Figure 186: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022

List of Tables

  • Table 1: Global Nucleic Acid Therapeutics CDMO Market, Key Developments Analysis, January 2018-February 2023
  • Table 2: Key Questions Answered in the Report
  • Table 3: Some of the Partnerships and Collaborations in the Global Nucleic Acid Therapeutics CDMO Market
  • Table 4: Global Nucleic Acid Therapeutics CDMO Market, Key Investment
  • Table 5: Global Regulatory Organization: Nucleic Acid Therapeutics CDMO Market
  • Table 6: Nucleic Acid Drugs Approved by FDA or EMA, 2018-2021
  • Table 7: Advancements in Manufacturing Units of CDMO
  • Table 8: Companies Offering Standard Nucleic Acid
  • Table 9: Companies Offering Micro-Scale Nucleic Acid
  • Table 10: Companies Offering Large-Scale Nucleic Acid
  • Table 11: Companies Offering Custom Nucleic Acid
  • Table 12: Companies Offering Modified Nucleic Acid
  • Table 13: Companies Offering Primers
  • Table 14: Some of the Companies Offering Probes
  • Table 15: Companies Offering Other Nucleic Acid
  • Table 16: Some of the Companies Offering Other Services
  • Table 17: Nucleic Acid Drugs in a phase 3 trial till June 2021
  • Table 18: North America Nucleic Acid Therapeutics CDMO Market, Impact Analysis
  • Table 19: Europe Nucleic Acid Therapeutic CDMO Market, Impact Analysis
  • Table 20: Asia-Pacific Nucleic Acid Therapeutics CDMO Market, Impact Analysis
  • Table 21: Rest-of-the-World Nucleic Acid Therapeutic CDMO Market, Impact Analysis